Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients
Language English Country United States Media print-electronic
Document type Journal Article, Review
PubMed
30160364
DOI
10.1002/pbc.27431
Knihovny.cz E-resources
- Keywords
- Ph+ leukemia, generic medication, imatinib inhibitor, pediatric, tyrosine kinase,
- MeSH
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy MeSH
- Child MeSH
- Drugs, Generic therapeutic use MeSH
- Imatinib Mesylate therapeutic use MeSH
- Protein Kinase Inhibitors therapeutic use MeSH
- Humans MeSH
- Antineoplastic Agents therapeutic use MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Drugs, Generic MeSH
- Imatinib Mesylate MeSH
- Protein Kinase Inhibitors MeSH
- Antineoplastic Agents MeSH
Since the patent for imatinib has expired, the role of generic imatinib (GI) in the management of Philadelphia chromosome-positive (Ph+) leukemia in pediatric patients has had ongoing discussion. Some studies in adults demonstrated that equivalent doses of GI and branded imatinib (BI) result in comparable plasma concentrations and clinical efficacy. However, other studies found that GI users are more likely to stop imatinib, with intolerance and decreased persistence as the main causes. Economic factors also heavily influence GI selection. This article aims to review the present knowledge to support further discussion on the role of GI in the management of pediatric Ph+ leukemia.
Department of Pediatric Hematology Uludağ University Hospital Görükle Bursa Turkey
Department of Pediatrics Keio University School of Medicine Tokyo Japan
Department of Pediatrics Tettamanti Research Center University of Milano Bicocca Monza Italy
Pediatric Hematology Immunology Department Paris Diderot University Paris France
Pediatric Hematology Immunology Department University Hospital Robert Debré Paris France
References provided by Crossref.org
